We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UNH vs. MOH: Which Insurer Can Better Navigate Current Volatility?
Read MoreHide Full Article
Key Takeaways
UnitedHealth benefits from unmatched scale and diversification across insurance and healthcare services.
UNH's Optum growth and strong cash help offset margin pressure from higher utilization.
Molina's Medicaid-heavy focus makes it more vulnerable to reimbursement changes and cost spikes.
UnitedHealth Group Incorporated (UNH - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) operate within the same highly regulated U.S. health insurance landscape, yet their business models, scale and exposure to policy risk differ meaningfully. With healthcare stocks facing renewed volatility amid policy uncertainty tied to President Trump’s proposed “Great Healthcare Plan,” investors are reassessing which insurers are better equipped to absorb regulatory shifts and cost pressures.
Both companies have deep exposure to government-sponsored programs, particularly Medicare and Medicaid, making them sensitive to reimbursement dynamics, medical cost trends and enrollment stability. However, their strategic positioning, diversification, and financial flexibility set them apart at a time when visibility across the sector remains limited.
Against this backdrop, investors are looking beyond near-term noise to identify insurers with the resilience and execution strength to navigate a volatile policy environment. Let’s closely compare the fundamentals of the two stocks to determine which one is better positioned to weather uncertainty.
The Case for UnitedHealth
UnitedHealth enters this period of volatility with unmatched scale and diversification across insurance and healthcare services. Through its UnitedHealthcare insurance arm and Optum platform, the company spans health benefits, pharmacy services, care delivery and data analytics, giving it multiple levers to offset margin pressure in any single segment. This integrated model provides earnings stability that few peers can replicate.
In its last reported quarter, UnitedHealth delivered steady revenue growth, supported by higher domestic commercial membership and continued expansion at Optum Rx. While margins faced pressure from higher utilization, management under CEO Stephen J. Hemsley, who returned to the role last May, reaffirmed its ability to rebalance pricing and care delivery over time. Optum’s growth, particularly in value-based care, continues to act as a stabilizing force when insurance margins fluctuate.
Profitability remains a key advantage for UNH. The company consistently generates strong operating cash flow, maintains disciplined capital deployment and benefits from scale-driven administrative efficiencies. Unlike smaller insurers, UnitedHealth can absorb short-term reimbursement changes without materially disrupting long-term earnings power, a critical edge in a shifting policy landscape.
That said, UnitedHealth is not immune to challenges. Heightened regulatory scrutiny continues to loom, with the current administration’s focus on PBMs potentially pressuring Optum Rx. At the same time, new disclosure and transparency mandates under the Great Healthcare Plan are likely to raise compliance costs and intensify competition by making cost and quality comparisons easier for consumers. While this could drive market share shifts, insurers with scale, data capabilities, operational depth and balance sheet strength — such as UnitedHealth — are better positioned to absorb the impact. Notably, UNH’s long-term debt-to-capital ratio of 43% remains below Molina’s 47.9%.
The Case for Molina Healthcare
Molina Healthcare has built a strong franchise within Medicaid-focused managed care, benefiting from steady enrollment growth and deep relationships with state governments. Its narrow focus has allowed the company to operate efficiently within its niche and deliver solid profitability during favorable rate cycles. MOH’s return on invested capital of 14.6% is significantly higher than 7.6% of UNH.
The company’s latest quarterly results also reflected stable revenue growth, driven by rising premiums, rate hikes and membership gains across multiple states. However, Molina remains more exposed to margin volatility tied to medical cost trends and state-level reimbursement decisions. Unlike UnitedHealth, Molina lacks a diversified services platform to offset insurance margin compression. MOH’s trailing 12-month EBITDA margin of 3.7% is lower than UNH’s 7.3%.
While Molina has made progress in improving operational discipline and cost controls, its earnings profile remains more sensitive to utilization spikes and regulatory shifts. Any unfavorable changes tied to healthcare reform proposals could disproportionately impact Molina, given its heavier reliance on government programs. Its medical care ratio (MCR) worsened from 88.1% in 2023 to 89.1% in 2024 and further to 92.6% in the third quarter of 2025. Meanwhile, UnitedHealth’s MCR also deteriorated and reached 89.9% in the third quarter of 2025, but remained below MOH’s level.
Molina’s smaller scale also limits its ability to negotiate provider pricing or absorb near-term disruptions. In contrast to UnitedHealth’s multi-engine growth model, Molina’s performance hinges more narrowly on execution within Medicaid, increasing earnings volatility during uncertain policy cycles.
Valuation: UNH vs. MOH
While Molina trades at a lower forward price-to-earnings multiple, UnitedHealth’s valuation better reflects earnings durability. UNH’s forward 12-month P/E of 18.64X is above MOH’s 13.92X and the industry average of 15.62X. Investors are paying for consistency, scale and visibility, which remain scarce in the current healthcare environment.
Image Source: Zacks Investment Research
How Do Zacks Estimates Compare for UNH & MOH?
Zacks estimates reflect a turnaround for UnitedHealth, supported by diversified earnings streams and consistent cash generation. The Zacks Consensus Estimate for UNH’s 2025 EPS is pegged at $16.30, indicating a 41.1% year-over-year decline. But the same for 2026 suggests an 8% increase to $17.60 per share. It beat earnings estimates twice in the past four quarters and missed on the other two occasions, with an average surprise of negative 2.3%.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
The consensus mark for Molina’s 2025 EPS is pegged at $13.95, a 38.4% decrease from a year ago. The same for 2026 predicts a 2.9% further decline to $13.55. It missed the earnings estimates thrice in the past four quarters and beat once, with an average surprise of negative 15.8%.
Molina Healthcare, Inc Price, Consensus and EPS Surprise
Shares of UnitedHealth have gained 17.3% in the past six months, outperforming Molina’s 8.4% growth, highlighting investor preference for stability. During this time, the industry and the S&P 500 have increased 14.2% and 12.8%, respectively.
6-Month Price Performance – UNH, MOH, Industry & S&P 500
Image Source: Zacks Investment Research
Conclusion
Overall, UnitedHealth stands out as the more resilient choice in a volatile healthcare environment. Its unmatched scale, diversified Optum-driven model, stronger profitability profile and healthier balance sheet provide multiple buffers against regulatory and cost pressures. While Molina offers focused Medicaid exposure, its narrower business mix leaves earnings more vulnerable to policy shifts and utilization swings.
With better earnings visibility, improving estimates beyond 2025 and clear relative price strength, UnitedHealth appears better positioned to navigate uncertainty and deliver more durable upside for investors. It currently has a Zacks Rank #3 (Hold), while Molina has a Zacks Rank #4 (Sell).
Image: Bigstock
UNH vs. MOH: Which Insurer Can Better Navigate Current Volatility?
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) operate within the same highly regulated U.S. health insurance landscape, yet their business models, scale and exposure to policy risk differ meaningfully. With healthcare stocks facing renewed volatility amid policy uncertainty tied to President Trump’s proposed “Great Healthcare Plan,” investors are reassessing which insurers are better equipped to absorb regulatory shifts and cost pressures.
Both companies have deep exposure to government-sponsored programs, particularly Medicare and Medicaid, making them sensitive to reimbursement dynamics, medical cost trends and enrollment stability. However, their strategic positioning, diversification, and financial flexibility set them apart at a time when visibility across the sector remains limited.
Against this backdrop, investors are looking beyond near-term noise to identify insurers with the resilience and execution strength to navigate a volatile policy environment. Let’s closely compare the fundamentals of the two stocks to determine which one is better positioned to weather uncertainty.
The Case for UnitedHealth
UnitedHealth enters this period of volatility with unmatched scale and diversification across insurance and healthcare services. Through its UnitedHealthcare insurance arm and Optum platform, the company spans health benefits, pharmacy services, care delivery and data analytics, giving it multiple levers to offset margin pressure in any single segment. This integrated model provides earnings stability that few peers can replicate.
In its last reported quarter, UnitedHealth delivered steady revenue growth, supported by higher domestic commercial membership and continued expansion at Optum Rx. While margins faced pressure from higher utilization, management under CEO Stephen J. Hemsley, who returned to the role last May, reaffirmed its ability to rebalance pricing and care delivery over time. Optum’s growth, particularly in value-based care, continues to act as a stabilizing force when insurance margins fluctuate.
Profitability remains a key advantage for UNH. The company consistently generates strong operating cash flow, maintains disciplined capital deployment and benefits from scale-driven administrative efficiencies. Unlike smaller insurers, UnitedHealth can absorb short-term reimbursement changes without materially disrupting long-term earnings power, a critical edge in a shifting policy landscape.
That said, UnitedHealth is not immune to challenges. Heightened regulatory scrutiny continues to loom, with the current administration’s focus on PBMs potentially pressuring Optum Rx. At the same time, new disclosure and transparency mandates under the Great Healthcare Plan are likely to raise compliance costs and intensify competition by making cost and quality comparisons easier for consumers. While this could drive market share shifts, insurers with scale, data capabilities, operational depth and balance sheet strength — such as UnitedHealth — are better positioned to absorb the impact. Notably, UNH’s long-term debt-to-capital ratio of 43% remains below Molina’s 47.9%.
The Case for Molina Healthcare
Molina Healthcare has built a strong franchise within Medicaid-focused managed care, benefiting from steady enrollment growth and deep relationships with state governments. Its narrow focus has allowed the company to operate efficiently within its niche and deliver solid profitability during favorable rate cycles. MOH’s return on invested capital of 14.6% is significantly higher than 7.6% of UNH.
The company’s latest quarterly results also reflected stable revenue growth, driven by rising premiums, rate hikes and membership gains across multiple states. However, Molina remains more exposed to margin volatility tied to medical cost trends and state-level reimbursement decisions. Unlike UnitedHealth, Molina lacks a diversified services platform to offset insurance margin compression. MOH’s trailing 12-month EBITDA margin of 3.7% is lower than UNH’s 7.3%.
While Molina has made progress in improving operational discipline and cost controls, its earnings profile remains more sensitive to utilization spikes and regulatory shifts. Any unfavorable changes tied to healthcare reform proposals could disproportionately impact Molina, given its heavier reliance on government programs. Its medical care ratio (MCR) worsened from 88.1% in 2023 to 89.1% in 2024 and further to 92.6% in the third quarter of 2025. Meanwhile, UnitedHealth’s MCR also deteriorated and reached 89.9% in the third quarter of 2025, but remained below MOH’s level.
Molina’s smaller scale also limits its ability to negotiate provider pricing or absorb near-term disruptions. In contrast to UnitedHealth’s multi-engine growth model, Molina’s performance hinges more narrowly on execution within Medicaid, increasing earnings volatility during uncertain policy cycles.
Valuation: UNH vs. MOH
While Molina trades at a lower forward price-to-earnings multiple, UnitedHealth’s valuation better reflects earnings durability. UNH’s forward 12-month P/E of 18.64X is above MOH’s 13.92X and the industry average of 15.62X. Investors are paying for consistency, scale and visibility, which remain scarce in the current healthcare environment.
How Do Zacks Estimates Compare for UNH & MOH?
Zacks estimates reflect a turnaround for UnitedHealth, supported by diversified earnings streams and consistent cash generation. The Zacks Consensus Estimate for UNH’s 2025 EPS is pegged at $16.30, indicating a 41.1% year-over-year decline. But the same for 2026 suggests an 8% increase to $17.60 per share. It beat earnings estimates twice in the past four quarters and missed on the other two occasions, with an average surprise of negative 2.3%.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote
The consensus mark for Molina’s 2025 EPS is pegged at $13.95, a 38.4% decrease from a year ago. The same for 2026 predicts a 2.9% further decline to $13.55. It missed the earnings estimates thrice in the past four quarters and beat once, with an average surprise of negative 15.8%.
Molina Healthcare, Inc Price, Consensus and EPS Surprise
Molina Healthcare, Inc price-consensus-eps-surprise-chart | Molina Healthcare, Inc Quote
Price Performance Comparison
Shares of UnitedHealth have gained 17.3% in the past six months, outperforming Molina’s 8.4% growth, highlighting investor preference for stability. During this time, the industry and the S&P 500 have increased 14.2% and 12.8%, respectively.
6-Month Price Performance – UNH, MOH, Industry & S&P 500
Conclusion
Overall, UnitedHealth stands out as the more resilient choice in a volatile healthcare environment. Its unmatched scale, diversified Optum-driven model, stronger profitability profile and healthier balance sheet provide multiple buffers against regulatory and cost pressures. While Molina offers focused Medicaid exposure, its narrower business mix leaves earnings more vulnerable to policy shifts and utilization swings.
With better earnings visibility, improving estimates beyond 2025 and clear relative price strength, UnitedHealth appears better positioned to navigate uncertainty and deliver more durable upside for investors. It currently has a Zacks Rank #3 (Hold), while Molina has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.